Telix Pharmaceuticals Limited (ASX:TLX)

Market Cap	8.89B
Revenue (ttm)	783.21M
Net Income (ttm)	49.92M
Shares Out	337.71M
EPS (ttm)	0.14
PE Ratio	182.02
Forward PE	67.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	725,030
Average Volume	2,211,532
Open	26.69
Previous Close	26.32
Day's Range	25.85 - 26.76
52-Week Range	12.01 - 31.97
Beta	2.49
RSI	46.45
Earnings Date	Apr 17, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: TLX

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.